TransMedics Group, Inc. Common Stock
TMDX
$68.94
+0.12%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy through its proprietary Organ Care System (OCS). The company operates as a disruptive innovator within the medical devices industry, specifically targeting the limitations of traditional cold storage for donor organs. The current investor narrative is dominated by the company's rapid commercial execution and transition to profitability, as evidenced by recent quarterly results showing explosive revenue growth and significant net income, though this is juxtaposed against a severe recent stock price decline that suggests market concerns over valuation or growth sustainability.…
TMDX
TransMedics Group, Inc. Common Stock
$68.94
Investment Opinion: Should I buy TMDX Today?
Rating & Thesis: Hold. TMDX presents a high-risk, high-potential-reward scenario where catastrophic technical damage conflicts with robust fundamental execution; investors should wait for evidence of a technical bottom or a clearer growth re-acceleration before establishing new positions, despite the attractive valuation compression.
Supporting Evidence: The stock trades at a forward P/E of 19.4x, a significant discount to its recent historical peaks, while analysts project strong forward EPS of $7.10. Revenue growth remains robust at 32% YoY, and profitability has surged with a net margin of 31.4%. The company generates positive free cash flow ($133.6M TTM) and has a fortress balance sheet (current ratio 7.14), mitigating near-term solvency risk. However, the severe price decline of 44% over the past year and negative momentum of -39.9% over one month indicate powerful selling pressure that may not be over.
Risks & Conditions: The two biggest risks are the continuation of the severe downtrend breaking the $60.11 support, and a confirmed deceleration in quarterly revenue growth. This Hold rating would upgrade to a Buy if the stock establishes a firm base above $60 and shows two consecutive quarters of re-accelerating sequential revenue growth. It would downgrade to a Sell if the stock breaks below $60 on high volume or if YoY revenue growth falls below 25%. On valuation, the stock appears fairly valued to slightly undervalued relative to its own growth trajectory but remains vulnerable to further de-rating if sentiment does not improve.
Sign up to view all
TMDX 12-Month Price Forecast
TMDX is a battleground stock caught between a compelling fundamental growth story and a technically destructive price trend. The AI assessment is neutral, as the risk of further downside from broken momentum is balanced by the potential for a sharp rebound if growth re-accelerates. Confidence is medium due to the high uncertainty surrounding near-term investor sentiment. The stance would upgrade to bullish on a confirmed technical reversal (e.g., a higher low above $70) coupled with a quarterly revenue beat. It would turn bearish on a breakdown below the $60.11 support level, which would signal a complete failure of the current valuation floor.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $89.62 and implied upside of +30.0% versus the current price.
Average Target
$89.62
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$55 - $90
Analyst target range
Analyst coverage appears limited with only 5 analysts providing estimates, and the available data focuses on future EPS and revenue estimates rather than price targets or ratings distributions, indicating insufficient data to determine a clear consensus price target or implied upside/downside. The wide range between the low and high revenue estimates for the forecast period ($1.20 billion vs. $1.24 billion) and EPS estimates ($7.00 vs. $7.26) signals a moderate degree of uncertainty among analysts regarding the company's near-term financial performance, which is typical for a commercial-stage med-tech company experiencing rapid growth and evolving profitability.
Bulls vs Bears: TMDX Investment Factors
The evidence presents a stark dichotomy: fundamentally, TMDX is executing superbly with explosive revenue growth, a dramatic profit turnaround, and a strong financial position. Technically, however, the stock is in freefall, having lost nearly half its value in a year with no signs of a bottom. The bear side currently has stronger near-term evidence due to the catastrophic price action and extreme negative momentum, which trumps the strong fundamentals. The single most important tension in the investment debate is whether the severe technical breakdown reflects a fundamental growth story that is permanently impaired (bear view) or an extreme overreaction creating a compelling entry point for a still-thriving business (bull view).
Bullish
- Explosive Revenue Growth & Profitability: The company reported Q4 2025 revenue of $160.76 million, a 32.18% year-over-year increase, demonstrating strong commercial traction. More impressively, net income surged to $105.38 million from $6.86 million a year ago, signaling a successful transition to profitability with a net margin of 31.4%.
- Strong Balance Sheet & Cash Flow: TransMedics boasts a robust current ratio of 7.14 and has generated $133.59 million in trailing twelve-month free cash flow. This strong liquidity position, coupled with a manageable debt-to-equity ratio of 0.99, provides a solid financial foundation to fund growth without immediate dilution risk.
- Attractive Valuation After Severe Correction: The stock's trailing P/E of 21.73x represents a dramatic compression from recent highs (e.g., 76.36x in Q4 2024), suggesting the valuation has normalized. The forward P/E of 19.39x implies an 11% discount to trailing earnings, pricing in modest growth expectations.
- High Analyst Growth Expectations: Analysts project average forward EPS of $7.10 and revenue of $1.22 billion, indicating confidence in continued strong performance. The PEG ratio of 0.05, calculated from the forward P/E and implied growth, suggests the stock is deeply undervalued relative to its expected growth rate, though this metric may be distorted.
Bearish
- Catastrophic Technical Breakdown: The stock is in a severe downtrend, trading at $68.94, which is just 5.7% of its 52-week range and down 44.11% over the past year. Recent momentum is devastating, with a 39.87% drop over the past month, indicating intense, persistent selling pressure and a complete lack of buyer support.
- Extreme Volatility & High Beta: With a beta of 2.061, TMDX is more than twice as volatile as the broader market, amplifying downside risk. The stock has suffered a maximum drawdown of -58.76%, and its severe underperformance versus the SPY (-44.71% over one month) highlights extreme company-specific risk.
- Potential Growth Deceleration: While year-over-year growth is strong at 32%, the most recent quarterly revenue of $160.76 million shows only a slight sequential increase from Q3's $143.82 million and is below Q2's $157.37 million. This pattern raises questions about the sustainability of the explosive growth narrative that previously supported its premium valuation.
- Premium Valuation Multiples Remain: Despite the price collapse, valuation metrics like the P/S ratio of 6.83x and P/B ratio of 8.74x remain elevated for a medical device company. The EV/EBITDA of 27.72x is high, indicating the stock is not cheap on an absolute basis and remains vulnerable to further multiple compression if growth falters.
TMDX Technical Analysis
The stock is in a pronounced and severe downtrend, having declined 44.11% over the past year and currently trading at just 5.7% of its 52-week range, based on a current price of $68.935 relative to a 52-week high of $156 and low of $60.105. This positioning deep in the lower tail of its annual range indicates extreme bearish momentum and suggests the stock is being treated as a 'falling knife' rather than a clear value opportunity. Recent momentum has been catastrophically negative, with the stock down 39.87% over the past month and 48.65% over the past three months, far exceeding the broader market's gains (SPY up 4.84% and 8.15% respectively) and highlighting severe company-specific or sector-specific selling pressure. Key technical levels are clearly defined, with immediate support at the 52-week low of $60.105 and formidable resistance far above at the 52-week high of $156; a breakdown below $60 would signal a complete breakdown of the long-term chart structure. The stock's beta of 2.061 confirms it is more than twice as volatile as the market, which amplifies both downside risk and potential for sharp rebounds, but the extreme negative relative strength readings (e.g., -44.71 vs. SPY over 1 month) underscore intense, persistent selling.
Beta
2.06
2.06x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-44.1%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | -39.9% | +4.4% |
| 3m | -48.7% | +9.3% |
| 6m | -47.3% | +10.5% |
| 1y | -44.1% | +28.8% |
| ytd | -43.8% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
Revenue growth is exceptionally strong but may be showing signs of sequential deceleration; the most recent quarterly revenue was $160.76 million, representing a robust 32.18% year-over-year increase, though this follows quarters with even higher sequential bases (e.g., Q2 2025 revenue was $157.37 million). The company has achieved a dramatic turnaround in profitability, reporting net income of $105.38 million and a gross margin of 58.11% for the latest quarter, a significant improvement from a net income of just $6.86 million and a gross margin of 59.21% in the year-ago quarter, indicating successful scaling and margin expansion. The balance sheet and cash flow position is solid, with a strong current ratio of 7.14, a manageable debt-to-equity ratio of 0.99, and positive free cash flow generation of $133.59 million on a trailing twelve-month basis, providing ample liquidity to fund operations internally without reliance on dilutive financing.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 21.73x, while the forward P/E is 19.39x, indicating the market expects modest earnings growth to continue, as the forward multiple represents an 11% discount to the trailing figure. Compared to its own historical range, the current trailing P/E of 21.73x is significantly below the peak multiples seen in recent quarters (e.g., 39.35x in Q3 2025 and 76.36x in Q4 2024), suggesting the valuation compression has been severe and the stock is trading at a more normalized, if not depressed, level relative to its own history, though still rich on an absolute basis given the recent price collapse.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: While profitability has improved dramatically, the company's valuation remains heavily reliant on sustaining high growth rates (32% YoY). Any deceleration in revenue growth, as hinted at by the flat sequential performance in recent quarters, could trigger significant multiple compression given its elevated P/S of 6.83x. Furthermore, the business is concentrated on a single product platform, the Organ Care System, creating revenue concentration risk. Although the balance sheet is strong now, the high beta of 2.061 indicates earnings and cash flows are likely perceived as volatile, which could pressure the stock during market downturns.
Market & Competitive Risks: The primary market risk is valuation compression. The stock has already seen its P/E compress from over 76x to 21.73x, but multiples like EV/EBITDA of 27.7x remain premium. If investor sentiment shifts away from high-growth, high-multiple stories, TMDX is exceptionally vulnerable. Competitive risks include the potential for new organ preservation technologies or improvements in traditional cold storage that could challenge the OCS's value proposition. The stock's extreme underperformance versus the market (SPY +4.84% vs. TMDX -39.87% over 1 month) suggests these risks are being aggressively priced in.
Worst-Case Scenario: The worst-case scenario involves a combination of growth deceleration below 20%, a broader market sell-off that punishes high-beta stocks, and a competitive or regulatory setback for the OCS platform. This could lead to a cascade of analyst downgrades and a re-rating to valuation multiples more in line with slower-growth med-tech peers. The realistic downside could see the stock break its 52-week low of $60.11 and approach levels implied by a P/E in the low teens, potentially resulting in a further 30-40% decline from the current price of $68.94, translating to a loss of -$20 to -$28 per share.
FAQ
The key risks are: 1) Technical & Sentiment Risk: The stock is in a severe downtrend with catastrophic momentum (-39.9% in 1 month), indicating a potential breakdown in investor confidence that could persist. 2) Growth Sustainability Risk: Revenue growth, while strong YoY, has shown flat sequential trends, raising questions about near-term acceleration. 3) Valuation Compression Risk: Even after the drop, multiples like P/S (6.83x) are high, leaving room for further de-rating. 4) Product Concentration Risk: The company's fortunes are tied to the success and adoption of its single Organ Care System platform. The high beta of 2.06 amplifies all these risks during market downturns.
The 12-month forecast is highly bifurcated, with three distinct scenarios. The base case (50% probability) sees the stock consolidating between $85 and $110 as growth meets expectations but sentiment remains cautious. The bull case (25% probability) projects a rally to $130-$156 on re-accelerating growth and restored confidence. The bear case (25% probability) warns of a drop to $50-$65 if growth decelerates and the technical breakdown continues below $60 support. The most likely outcome is the base case, assuming the company executes on its current plan without major surprises, but the extreme volatility makes any forecast highly uncertain.
TMDX's valuation is in a state of flux. On one hand, its trailing P/E of 21.73x is significantly below its own historical peaks (e.g., 76x), suggesting it is undervalued relative to its recent past. On an absolute basis, a P/S ratio of 6.83x and EV/EBITDA of 27.7x are still premium, indicating the market expects continued high growth. Compared to the broader market, it is expensive, but for its growth rate, the forward P/E of 19.4x could be considered reasonable if growth is sustained. The valuation is fair to slightly undervalued if the 32% growth persists, but remains vulnerable to being deemed overvalued if that growth decelerates.
TMDX is a high-risk, high-reward proposition and is not a straightforward 'good buy' for all investors. For aggressive growth investors with a long-term horizon and the stomach for extreme volatility (beta 2.06), the current price, down 44% from its high, may represent an attractive entry point into a company with 32% revenue growth and strong profitability. However, given the catastrophic technical breakdown and -39.9% one-month decline, the stock is a 'falling knife,' and most investors should wait for a confirmed bottom and stabilization in price action before considering a purchase. The key is whether you believe the fundamental story remains intact despite the market's punishment.
TMDX is unsuitable for short-term trading or speculation due to its extreme volatility (beta 2.061) and current 'falling knife' status. It is strictly a long-term investment for investors who believe in the multi-year disruption story of the OCS platform and can tolerate significant drawdowns (the stock has already seen a -58.76% max drawdown). A minimum holding period of 3-5 years is suggested to allow the commercial story to play out and for the current severe sentiment washout to subside. The lack of a dividend further reinforces its role as a pure capital appreciation vehicle for the long term.